Baseline characteristics

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) · Source last updated 2023-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      475

   units

   Participants

groups

1. description

   Participants received pembrolizumab 10 mg/kg IV over 30 minutes once every 2 weeks (Q2W) for up to \~2 years. Qualified participants who completed the first course of pembrolizumab treatment but progressed after discontinuation were eligible for a second course of pembrolizumab at 10 mg/kg IV Q2W for up to \~1 additional year, at the Investigator's discretion. Per protocol participants were presented by treatment received in the single arm study.

   id

   BG000

   title

   Pembrolizumab (MK-3475) 10 mg/kg

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            11.7

            value

            58.7

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   Years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            281

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            194

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            18

         title

         Hispanic or Latino

      2. measurements

         1. group Id

            BG000

            value

            380

         title

         Not Hispanic or Latino

      3. measurements

         1. group Id

            BG000

            value

            77

         title

         Unknown or Not Reported

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Ethnicity (NIH/OMB)

   unit Of Measure

   Participants

4. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         title

         American Indian or Alaska Native

      2. measurements

         1. group Id

            BG000

            value

            99

         title

         Asian

      3. measurements

         1. group Id

            BG000

            value

            0

         title

         Native Hawaiian or Other Pacific Islander

      4. measurements

         1. group Id

            BG000

            value

            20

         title

         Black or African American

      5. measurements

         1. group Id

            BG000

            value

            280

         title

         White

      6. measurements

         1. group Id

            BG000

            value

            2

         title

         More than one race

      7. measurements

         1. group Id

            BG000

            value

            73

         title

         Unknown or Not Reported

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race (NIH/OMB)

   unit Of Measure

   Participants

population Description

The analysis population consisted of all allocated participants who received at least one dose of study drug. Per protocol, Baseline Characteristics were summarized by treatment dose.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice